newsfilter
← Latest News
GlobeNewswire·

Standard BioTools Reports Second Quarter 2024 Financial Results

Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA